Skip to main content
Year archive

Egetis Therapeutics — 2023 filings

All 43 regulatory filings released by Egetis Therapeutics (EGTX) in 2023, sourced directly from the official regulator.

43 Filings
2023 Period
2023 filings (43)
Filing Released Lang
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
Environmental & Social Information
2023-11-10 English
Egetis ingår exklusivt licensavtal med Fujimoto för att utveckla och kommersialisera Emcitate i Japan
Regulatory Filings
2023-11-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-08 English
Egetis Therapeutics har beslutat om riktade emissioner av teckningsoptioner och en konvertibel inom ramen för utnyttjande av Tranche A av den tidigare kommunicerade skuldfinansieringen
Share Issue/Capital Change
2023-11-07 Swedish
Egetis Therapeutics has resolved on directed issues of warrants and a convertible bond within the framework of the drawdown of Tranche A of the previously communicated debt financing
Capital/Financing Update
2023-11-07 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-02 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-01 English
Egetis valberedning utsedd inför årsstämman 2024
AGM Information
2023-11-01 Swedish
Egetis’ Nomination Committee for the 2024 Annual General Meeting
AGM Information
2023-11-01 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2023-10-31 Swedish
Change in the number of shares and votes in Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2023-10-31 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-10-12 English
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
Report Publication Announcement
2023-10-11 English
Egetis Therapeutics offentliggör prospekt för upptagande till handel av aktier, i den riktade emissionen, på Nasdaq Stockholm
Capital/Financing Update
2023-10-11 Swedish
Egetis Therapeutics has secured approximately SEK 462 million in a combined financing comprising a SEK 172 million equity private placement and SEK 290 million debt financing
Share Issue/Capital Change
2023-10-10 English
Egetis Therapeutics har säkrat cirka 462 miljoner kronor i en kombinerad finansiering bestående av en riktad nyemission om 172 miljoner kronor och en skuldfinansiering om 290 miljoner kronor
Capital/Financing Update
2023-10-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-22 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-22 English
Egetis tillkännager aktivering av första deltagande sjukhus för den i USA registreringsgrundande ReTRIACt studien för Emcitate® och ger en uppdatering om tidslinjer gällande marknadsföringsansökan i U
Regulatory Filings
2023-06-28 Swedish
Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission
Regulatory Filings
2023-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-13 English
Board director in Egetis Therapeutics acquires shares
Director's Dealing
2023-05-31 English
Styrelseledamot i Egetis Therapeutics förvärvar aktier
Director's Dealing
2023-05-31 Swedish
Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update
Regulatory Filings
2023-05-23 English
Egetis meddelar att diskussionerna om ett potentiellt förvärv av Bolaget har avslutats samt ger en bolagsuppdatering
M&A Activity
2023-05-23 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2023
AGM Information
2023-04-27 English
Kommuniké från Egetis Therapeutics årsstämma 2023
AGM Information
2023-04-27 Swedish
Earnings Release 2023
Earnings Release Q2 2023
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-04-26 English
Egetis comments on market rumors
Legal Proceedings Report
2023-03-30 English
Egetis kommenterar förekommande rykten på marknaden
M&A Activity
2023-03-30 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-03-28 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
AGM Information
2023-03-23 English
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
AGM Information
2023-03-23 Swedish
Earnings Release 2022
Earnings Release FY 2022
2023-02-22 Swedish
Audit Report / Information 2022
Audit Report / Information FY 2022
2023-02-22 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 Swedish
Change in the number of shares and votes in Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission om 210 miljoner kronor
Capital/Financing Update
2023-01-25 Swedish
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million
Share Issue/Capital Change
2023-01-25 English
Egetis Therapeutics offentliggör avsikten att genomföra en riktad nyemission om cirka 200 miljoner kronor
Capital/Financing Update
2023-01-24 Swedish
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million
Capital/Financing Update
2023-01-24 English